Hallux Valgus and Bunion
Conditions
Brief summary
This is a Phase 2b, randomized, double blind, placebo and active controlled study with an Ascending Dose Stage and an optional Dose Expansion Stage in subjects undergoing bunionectomy.
Detailed description
Near the completion of surgery, a single dose of study drug (CPL-01, saline placebo, or ropivacaine HCl) will be infiltrated. Subjects will remain in the hospital/research facility for a minimum of 72 hours after the start of study drug administration to undergo postoperative assessments. Subjects will return to the study site on Day 7 to complete follow up assessments, on Day 28 for follow-up assessments including an X-Ray, and on Day 42 for the end-of-study (EOS) visit.
Interventions
DRUGAnalgesic Non Narcotic
Injection of protocol-specified volume of local analgesic
Sponsors
Cali Pharmaceuticals LLC
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Separate blinded and unblinded study teams
Intervention model description
Bunion Surgery
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Be willing and able to sign the informed consent form (ICF) prior to study participation * In the medical judgment of the Investigator, be a reasonably healthy adult 18 - 75 years of age, inclusive, and ASA Class I or II at the time of randomization * Plan to undergo an elective primary unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation under regional anesthesia, without collateral procedures or additional surgeries * Have a BMI ≤ 39 kg/m2
Exclusion criteria
* Previous unilateral simple bunionectomy * Has a planned concurrent surgical procedure that may impact pain scores, rescue medication use, or ability to fulfill the requirements of the protocol * Concurrent painful condition * Active skin disease or other clinically significant abnormality at the anticipated surgical site that could interfere with the planned surgery * Known hypersensitivity or known allergy, as determined by the Investigator, to the ingredients (i.e., excipients) of the study drug or any peri- or postoperative medications used in this study * History or clinical manifestation of significant medical, neuropsychiatric, or other condition that could preclude or impair study participation or interfere with study assessments * History of malignant hyperthermia or glucose-6-phosphate dehydrogenase deficiency * History or evidence of impaired liver function (e.g., ALT \> 3 × upper limit of normal \[ULN\] or total bilirubin \> 2 × ULN), active hepatic disease, or cirrhosis * History or evidence of impaired renal function (e.g., creatinine \> 1.5 × ULN) * History of malignancy in the past year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized in situ carcinoma of the cervix * Has or has had active COVID-19 infection within 3 months prior to surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC72 | 72 hours post-operative | Pain score through 72 hours post-operative |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Opioid use (MME) | 72 hours post-operative | Opioid use through 72 hours post-operative |
Countries
United States
Outcome results
None listed